MRVI vs. TGTX, AXSM, KRYS, VRNA, OGN, SRRK, ALVO, BHVN, ADMA, and APLS
Should you be buying Maravai LifeSciences stock or one of its competitors? The main competitors of Maravai LifeSciences include TG Therapeutics (TGTX), Axsome Therapeutics (AXSM), Krystal Biotech (KRYS), Verona Pharma (VRNA), Organon & Co. (OGN), Scholar Rock (SRRK), Alvotech (ALVO), Biohaven (BHVN), ADMA Biologics (ADMA), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical products" industry.
Maravai LifeSciences vs.
TG Therapeutics (NASDAQ:TGTX) and Maravai LifeSciences (NASDAQ:MRVI) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, community ranking, analyst recommendations, profitability and valuation.
TG Therapeutics has higher earnings, but lower revenue than Maravai LifeSciences. TG Therapeutics is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, TG Therapeutics had 4 more articles in the media than Maravai LifeSciences. MarketBeat recorded 9 mentions for TG Therapeutics and 5 mentions for Maravai LifeSciences. TG Therapeutics' average media sentiment score of 1.01 beat Maravai LifeSciences' score of 0.45 indicating that TG Therapeutics is being referred to more favorably in the media.
TG Therapeutics has a net margin of -5.42% compared to Maravai LifeSciences' net margin of -81.13%. Maravai LifeSciences' return on equity of -6.61% beat TG Therapeutics' return on equity.
TG Therapeutics received 596 more outperform votes than Maravai LifeSciences when rated by MarketBeat users. Likewise, 76.42% of users gave TG Therapeutics an outperform vote while only 62.63% of users gave Maravai LifeSciences an outperform vote.
TG Therapeutics presently has a consensus price target of $40.67, suggesting a potential upside of 30.09%. Maravai LifeSciences has a consensus price target of $10.28, suggesting a potential upside of 82.94%. Given Maravai LifeSciences' higher probable upside, analysts clearly believe Maravai LifeSciences is more favorable than TG Therapeutics.
58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 10.5% of TG Therapeutics shares are held by company insiders. Comparatively, 0.6% of Maravai LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
TG Therapeutics has a beta of 2.24, suggesting that its share price is 124% more volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of -0.07, suggesting that its share price is 107% less volatile than the S&P 500.
Summary
TG Therapeutics beats Maravai LifeSciences on 13 of the 17 factors compared between the two stocks.
Get Maravai LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Maravai LifeSciences Competitors List
Related Companies and Tools
This page (NASDAQ:MRVI) was last updated on 1/27/2025 by MarketBeat.com Staff
